Novartis AG

Swiss Stock Exchange:NOVN.SW

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

🧬 Biotechnology

🔬 Clinical Trials

Location

Switzerland

Market Cap

USD 236.46 B

Share Price

USD 119.72

Avg Daily Volume

4,098,771

Change (1 day)

-1.03%

Change (1 year)

13.62%

Change (YTD)

22.06%

Novartis AG Price to Book Ratio (P/B) on June 13, 2025: 5.37

Novartis AG Price to Book Ratio (P/B) is 5.37 on June 13, 2025, a 17.07% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Novartis AG 52-week low Price to Book Ratio (P/B) is 5.42 on June 13, 2025, which is 1.04% above the current Price to Book Ratio (P/B).
Novartis AG 52-week low Price to Book Ratio (P/B) is 4.15 on June 13, 2025, which is -22.74% below the current Price to Book Ratio (P/B).
Novartis AG average Price to Book Ratio (P/B) for the last 52 weeks is 4.82.

Daily

From:

To:

Zoom:

Key data

Date	Price to Book Ratio (P/B)	Price to Sales Ratio (P/S)	Enterprise Value to EBITDA (EV/EBITDA)	Free Cash Flow Yield

Swiss Stock Exchange: NOVN.SW

Novartis AG

CEO	Dr. Vasant Narasimhan M.D.
IPO Date	Aug. 3, 1995
Location	Switzerland
Headquarters	Lichtstrasse 35
Employees	75,883
Sector	🏥 Health Care
Industries Pharmaceuticals 🧬 Biotechnology 🔬 Clinical Trials

Description

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.